drugset
drugset / Trial / NCT06238856

Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

NCT06238856 ↗

Phase 1 Completed 18 enrolled Insmed Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.

Timeline

Start
2004-05-12
Primary completion
2005-02-08
Completion
2005-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amikacin Small molecule — Inhaled

Indications

cystic fibrosis